Company Bioheart, Inc. Other OTC
Equities
US09062F2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Autologous Cell Therapies
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 31/12/02 |
Mark Borman
CHM | Chairman | 69 | 30/04/09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 04/03/17 |
Director/Board Member | 100 | 31/05/03 | |
Mark Borman
CHM | Chairman | 69 | 30/04/09 |
Miguel Tomás
CEO | Chief Executive Officer | 58 | 31/12/02 |
Sheldon Anderson
BRD | Director/Board Member | 73 | 27/08/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 641,507,317 | 571,247,298 ( 89.05 %) | 0 | 89.05 % |
Company contact information
U.S. Stem Cell, Inc.
1560 Sawgrass Corporate Parkway 4th floor
33323-6217, Sunrise
+954 835 1500
http://www.us-stemcell.com![address Bioheart, Inc.](https://cdn.zonebourse.com/static/address/11095482.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.45% | 122B | |
+21.96% | 116B | |
+25.15% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-16.40% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- USRM Stock
- Stock
- Company Bioheart, Inc.